Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus

Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus

(2016) D. J. Kazierad et al.   DIABETES OBESITY & METABOLISM

Glucagon orchestrates stress-induced hyperglycaemia

(2016) J. B. Harp et al.   DIABETES OBESITY & METABOLISM

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

(2015) Christof M. Kazda et al.   DIABETES CARE

Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

(2015) R. P. Kelly et al.   DIABETES OBESITY & METABOLISM

Inhibiting or antagonizing glucagon: making progress in diabetes care

(2015) P. J. Lefèbvre et al.   DIABETES OBESITY & METABOLISM

Discovery of a Novel Glucagon Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes

(2012) Yusheng Xiong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Glucagon antagonism as a potential therapeutic target in type 2 diabetes

(2011) J. I. Bagger et al.   DIABETES OBESITY & METABOLISM

Pathogenesis of Fasting and Postprandial Hyperglycemia in Type 2 Diabetes: Implications for Therapy

(2010) R. A. Rizza   DIABETES

Human Glucagon Receptor Antagonists with Thiazole Cores. A Novel Series with Superior Pharmacokinetic Properties

(2009) Peter Madsen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys

(2009) H. Yan et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible  -Cell Hyperplasia and Hyperglucagonemia

(2009) W. Gu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes

(2008) Safina Ali et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Translating the A1C Assay Into Estimated Average Glucose Values

(2008) D. M. Nathan et al.   DIABETES CARE